Market Overview:
The global anti hepatitis virus drugs market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hepatitis viruses, rising awareness about available treatments, and technological advancements in the field of antiviral drugs. The global anti hepatitis virus drugs market can be segmented on the basis of type into nucleos(t)ide analogues, direct-acting antiviral agents (DAAs), and interferon alfa. The nucleos(t)ide analogue segment is expected to account for the largest share of the global anti hepatitis virus drugs market in 2018 owing to its high efficacy and safety profile. The direct-acting antiviral agent segment is projected to grow at a higher CAGR than other segments during the forecast period due to increasing adoption rates for these agents due their high efficacy and tolerability profiles. On the basis of application,the global antihepatitis virus drugsmarket can be divided intohepatitis B, HCV,and other applications such as non-alcoholic fatty liver disease (NAFLD), primary biliary cirrhosis (PBC), cryptogenic cirrhosis (CC), and posttransplantation recurrence prevention among others).
Product Definition:
There are a few different types of anti-hepatitis virus drugs. The most common type is called a "protease inhibitor." This drug helps to stop the virus from multiplying in the body. It is important to take these drugs as prescribed by your doctor in order to help clear the infection and prevent further damage to your liver.
Nucleos(t)ide Analogues:
Nucleoside analogues are the class of drugs that act on liver enzymes to inhibit them from converting RNA into DNA. The inhibition leads to a decrease in the production of new hepatitis viruses.
Global Nucleos(t)ide Analogues, usage.
Direct-acting Antiviral Dgents (DAAs):
Direct-acting antiviral drugs are the ones that act against the virus and do not require an immune response from the host. They can either be administered to a patient already suffering from an infection or as prophylaxis (prevention) against future infections. The first DAA was introduced in 1994, which was Alimta by Merck & Co., Inc.
Application Insights:
Based on the application, the global anti-hepatitis virus drugs market is segmented into hepatitis B, hepatitis C & co-infection (HBV/HCV), and other types. The hepatitis C and co-infection segment held a major share in 2017 owing to increasing prevalence of chronic liver diseases. According to WHO, an estimated 90% of people with HCV are not aware that they have the infection. Thus, there is a high demand for effective treatment options for viral infections of the liver which will drive growth during forecast years.
The HBV/HCV segment is expected to grow at fastest rate during forecast period due to rising incidence rates of chronic HBVs infection.
Regional Analysis:
North America dominated the global market in 2017. The presence of key manufacturers, availability of effective treatment and high awareness levels are some factors responsible for its large share. In addition, increasing cases of hepatitis are also expected to drive the demand for anti-hepatitis virus drugs in this region. For instance, as per CDC’s National Center for Health Statistics (NCHS), from 2015 to 2016 there was a rise in reported cases of acute hepatitis B infection from 3,943 cases in 2014 to 4,869 cases in 2016 among U.
Asia Pacific is expected to be the fastest growing region over the forecast period owing to rising prevalence rates and awareness campaigns regarding HCV infections being conducted by various organizations such as WHO & UNICEF along with government agencies such as Global Initiative on Anti-Hepatitis A&B Virus (GIAVA).
Growth Factors:
- Increasing incidence of hepatitis viruses across the globe
- Growing awareness about the prevention and treatment of hepatitis viruses
- Rising demand for anti-hepatitis drugs in developing countries
- Technological advancements in the development of anti-hepatitis drugs
- increasing funding for research and development on anti-hepatitis drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti Hepatitis Virus Drugs Market Research Report
By Type
Nucleos(t)ide Analogues, Direct-acting Antiviral Dgents (DAAs), Interferon Alfa
By Application
Hepatitis B, HCV, Other
By Companies
Novartis, Roche, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, AbbVie, Gilead Sciences, CHIATAI TIANQING, Cosunter Pharmaceutical, Qingfeng Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
175
Number of Tables & Figures
123
Customization Available
Yes, the report can be customized as per your need.
Global Anti Hepatitis Virus Drugs Market Report Segments:
The global Anti Hepatitis Virus Drugs market is segmented on the basis of:
Types
Nucleos(t)ide Analogues, Direct-acting Antiviral Dgents (DAAs), Interferon Alfa
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatitis B, HCV, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Roche
- Bristol Myers Squibb
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- AbbVie
- Gilead Sciences
- CHIATAI TIANQING
- Cosunter Pharmaceutical
- Qingfeng Pharmaceutical
Highlights of The Anti Hepatitis Virus Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Nucleos(t)ide Analogues
- Direct-acting Antiviral Dgents (DAAs)
- Interferon Alfa
- By Application:
- Hepatitis B
- HCV
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti Hepatitis Virus Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anti-Hepatitis virus drugs are medications that help to prevent or treat hepatitis. These drugs can be used to treat both acute and chronic forms of hepatitis.
Some of the major companies in the anti hepatitis virus drugs market are Novartis, Roche, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, AbbVie, Gilead Sciences, CHIATAI TIANQING, Cosunter Pharmaceutical, Qingfeng Pharmaceutical.
The anti hepatitis virus drugs market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti Hepatitis Virus Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti Hepatitis Virus Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti Hepatitis Virus Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti Hepatitis Virus Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti Hepatitis Virus Drugs Market Size & Forecast, 2018-2028
4.5.1 Anti Hepatitis Virus Drugs Market Size and Y-o-Y Growth
4.5.2 Anti Hepatitis Virus Drugs Market Absolute $ Opportunity
Chapter 5 Global Anti Hepatitis Virus Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Anti Hepatitis Virus Drugs Market Size Forecast by Type
5.2.1 Nucleos(t)ide Analogues
5.2.2 Direct-acting Antiviral Dgents (DAAs)
5.2.3 Interferon Alfa
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Anti Hepatitis Virus Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Anti Hepatitis Virus Drugs Market Size Forecast by Applications
6.2.1 Hepatitis B
6.2.2 HCV
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anti Hepatitis Virus Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti Hepatitis Virus Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anti Hepatitis Virus Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Anti Hepatitis Virus Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anti Hepatitis Virus Drugs Market Size Forecast by Type
9.6.1 Nucleos(t)ide Analogues
9.6.2 Direct-acting Antiviral Dgents (DAAs)
9.6.3 Interferon Alfa
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Anti Hepatitis Virus Drugs Market Size Forecast by Applications
9.10.1 Hepatitis B
9.10.2 HCV
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Anti Hepatitis Virus Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Anti Hepatitis Virus Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anti Hepatitis Virus Drugs Market Size Forecast by Type
10.6.1 Nucleos(t)ide Analogues
10.6.2 Direct-acting Antiviral Dgents (DAAs)
10.6.3 Interferon Alfa
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Anti Hepatitis Virus Drugs Market Size Forecast by Applications
10.10.1 Hepatitis B
10.10.2 HCV
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Anti Hepatitis Virus Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anti Hepatitis Virus Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anti Hepatitis Virus Drugs Market Size Forecast by Type
11.6.1 Nucleos(t)ide Analogues
11.6.2 Direct-acting Antiviral Dgents (DAAs)
11.6.3 Interferon Alfa
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Anti Hepatitis Virus Drugs Market Size Forecast by Applications
11.10.1 Hepatitis B
11.10.2 HCV
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Anti Hepatitis Virus Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Anti Hepatitis Virus Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anti Hepatitis Virus Drugs Market Size Forecast by Type
12.6.1 Nucleos(t)ide Analogues
12.6.2 Direct-acting Antiviral Dgents (DAAs)
12.6.3 Interferon Alfa
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Anti Hepatitis Virus Drugs Market Size Forecast by Applications
12.10.1 Hepatitis B
12.10.2 HCV
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Anti Hepatitis Virus Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anti Hepatitis Virus Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anti Hepatitis Virus Drugs Market Size Forecast by Type
13.6.1 Nucleos(t)ide Analogues
13.6.2 Direct-acting Antiviral Dgents (DAAs)
13.6.3 Interferon Alfa
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Anti Hepatitis Virus Drugs Market Size Forecast by Applications
13.10.1 Hepatitis B
13.10.2 HCV
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anti Hepatitis Virus Drugs Market: Competitive Dashboard
14.2 Global Anti Hepatitis Virus Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Roche
14.3.3 Bristol Myers Squibb
14.3.4 GlaxoSmithKline
14.3.5 Johnson & Johnson
14.3.6 Merck
14.3.7 AbbVie
14.3.8 Gilead Sciences
14.3.9 CHIATAI TIANQING
14.3.10 Cosunter Pharmaceutical
14.3.11 Qingfeng Pharmaceutical
